Pain associated with diabetic peripheral neuropathy: A review of available treatments

P and T

Volumn 33, Issue 3, 2008, Pages 166-179

  St Onge, Erin L ^a   Miller, Shannon A ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CAPSAICIN; CLOMIPRAMINE; DESIPRAMINE; DIAZEPAM; DOXEPIN; DULOXETINE; GABAPENTIN; IBUPROFEN; IMIPRAMINE; LAMOTRIGINE; LIDOCAINE; NORADRENALIN; NORTRIPTYLINE; OXCARBAZEPINE; OXYCODONE; PARACETAMOL; PERCOCET; PLACEBO; PREGABALIN; PROTRIPTYLINE; SEROTONIN; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VITAMIN B GROUP;

ABDOMINAL PAIN; ABNORMAL VISION; AGE; ANALGESIC ACTIVITY; ANOREXIA; ANTICHOLINERGIC EFFECT; APPLICATION SITE BURNING; ASTHENIA; ATAXIA; BLURRED VISION; CIGARETTE SMOKING; CLINICAL TRIAL; CLUSTER HEADACHE; COMORBIDITY; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIAGNOSTIC APPROACH ROUTE; DIPLOPIA; DISEASE ASSOCIATION; DISEASE DURATION; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DYSPEPSIA; FATIGUE; FOLLOW UP; FOOT CARE; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; IMPOTENCE; INSOMNIA; LIPID METABOLISM; MIGRAINE; MORBIDITY; MORTALITY; NAUSEA; NEUROPATHIC PAIN; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRURITUS; REVIEW; RHINITIS; RISK FACTOR; RISK REDUCTION; SEDATION; SIDE EFFECT; SOMNOLENCE; SWEATING; THROMBOCYTE METABOLISM; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VASCULAR TISSUE; VERTIGO; VISUAL ANALOG SCALE; VOMITING; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 42149110903     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: An intensive review. Am J Hosp Pharm 2004;61:160-173.
2. American Diabetes Association. Standards of Medical Care in Diabetes 2007. Diabetes Care 2007;30(Supp 1):S4-S41.
3. Tseng CH. Prevalence of lower-extremity amputation among patients with diabetes mellitus: Is height a factor? Can Med Assoc J 2006;31:174(3):319-323.
4. Head KA. Peripheral neuropathy: Pathogenic mechanisms and alternative therapies. Altern Med Rev 2006;11(4):294-329.
5. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-596.
6. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: Treatment planning and options. Mayo Clin Proc 2006;81(4 Suppl):S12-S25.
7. Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother 1999;33:996-1000.
8. McQuay HJ, Tramer M, Carroll ND, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-227.
9. Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989;37:151-153.
10. Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA 1984;251:1727-1730.
11. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980;243:1147-1150.
12. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain 1991;45:3-9.
13. Max MB, Lynch SU, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
14. Cymbalta (duloxetine), package insert. Indianapolis, IN: Eli Lilly; 2007.
15. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;36:383-390.
16. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36(4):106-132.
17. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Efficacy and safety of duloxetine 120 mg/day in the treatment of depression. J Affect Disord 2002;68:108.
18. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118.
19. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-356.
20. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long term treatment of diabetic peripheral neuropathic pain. J Palliat Med 2006;9(1):29-40.
21. Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook, 13th ed. Cleveland, OH: Lexicomp, Inc.; 2005.
22. Rowbotham MC, Golil V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;(110):697-706.
23. Sindrup SH, Bach BW, Madsen C, et al. Venlafaxine versus Imipramine in painful polyneuropathy. Neurology 2003;60:1284-1289.
24. Gorson KC, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: A placebo-controlled, double-blind, cross-over trial. J Neurol Neurosurg Psychiatry 1999;66:251-252.
25. Backonja M, Beydoun A, Edwards K, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280(21):1831-1836.
26. Morello CM, Leckband SG, Stoner CP. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-1937.
27. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. J Pain Symptom Manage 2000;20(4):280-285.
28. Frampton JE, Scott LJ. Pregabalin in the treatment of painful diabetic peripheral neuropathy. Drugs 2004;64(24):2813-2820.
29. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104-2110.
30. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004;110(3):628-638.
31. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005;6(4):253-260.
32. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-263.
33. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: A randomized, placebo-controlled study. Eur J Pain 2005;9:543-554.
34. Beydoun A, Shaibani a, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study Acta Neurol Scand 2006;113:395-404.
35. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:177-180.
36. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neurotherapy: A randomized, controlled study. Neurology 2001;57:505-509.
37. Vinik A Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain 2007;128:169-179.
38. Jose V, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Med 2007;24:377-383.
39. Lidoderm (Lidocaine), package insert. Chadds Ford, PA: Endo; 2006.
40. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study. Pain 2003;106(1-2):151-158.
41. Barbano RL, Hermann DN, Hari-Goulea S, et al. Effectiveness, tolerability and impact of quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914-918.
42. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: Assessment with the neuropathic pain scale. Curr Med Res Opin 2004;20(2):S21-S28.
43. Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther 2004;26(7):951-979.
44. Donofrio P, Walker F, Hunt V, et al. (Capsaicin Study Group). Treatment of painful diabetic neuropathy with topical capsaicin. Arch Intern Med 1991;151:2225-2229.
45. Donofrio P, Walker F, Hunt V, et al. (Capsaicin Study Group). Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992;15(2):159-165.
46. Gimbel J, Richards P, Portenoy R. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003;60:927-934.
47. Watson C, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-78.
48. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65-70.
49. Freeman R, Raskin R Hewitt D, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 2007;23(1):147-161.
50. Metanx. Available at: www.metanx.com/Healthcare Professionals, MedicalReferences. Accessed August 3, 2007.
51. Buysschaert M, Dramais AS, Wallemacq PD, et al. Hyperhomocysteinemia in type 2 diabetes: Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23(12):1816-1822.
52. De Luis DA, Fernandez N, Arranz ML, et al. Total homocysteine levels: Relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. J Diabetes Complications 2005;19(1):42-46.
53. Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabetes Med 2001;18(3):185-192.
54. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs. placebo in painful diabetic neuropathy. Neurology 2004;63:865-873.
55. Donofrio P, Raskin P, Rosenthal N, et al. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther 2005;27(9):1420-1431.
56. Thienel U, Neto W, Schwabe S, Vijapurkar U, for the Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: Findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004;110:221-231.
57. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60(11)1524-1534.
58. Gilron I, Watson PN, Cahill CM, et al. Neuropathic pain: A practical guide for the clinician. Can Med Assoc J 2006;175(3):265-275.
59. Finnerup NB, Otto M, Jensen TS, et al. An evidence based algorithm for the treatment of neuropathic pain. Medscape Gen Med 2007;9(2):36.
60. Stanos S. Appropriate use of opioid analgesics in chronic pain. J Fam Practice 2007;56(Suppl 2):23-32.
61. Ahmad M, Goucke CR. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 2002;19(12): 929-945.
62. Lackner TE. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy 2002;22(3):329-364.
63. Gallagher RM. Management of neuropathic pain. Clin J Pain 2006;22(1):S2-S8.